Investing Profile

Kate Bingham

Photo of Kate Bingham, Managing Partner at SV Health Investors

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard Business School Network
430 CONNECTIONS
University of Oxford Network
96 CONNECTIONS
cb
SV Health Investors Managing Partner
$30K - $3.0M
$1.5M
3
£200M
CompanyStageDateRound SizeTotal Raised
Alchemab Therapeutics
Series ASep 2025$32M
$120M
Co-investors: Andrew Levin (RA Capital), Houman Ashrafian (SV Health Investors)
Eyebiotech
Series ANov 2023$65M
Series AFeb 2022$65M
$130M
Co-investors: Mike Ross (SV Health Investors), Bernard Davitian (Omega Funds)
Managing Partner SV Life Sciences1991 - Present
Harvard Business School MBA Business
University of Oxford BA Biochemistry